… Molnupiravir was granted emergency use authorization for the treatment of mild to moderate
coronavirus disease 2019 (COVID-… -world data to evaluate the effectiveness of molnupiravir. …

… mild to moderate coronavirus disease 2019 (COVID–19) who are at risk for progression. …
evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-…

… topline safety and efficacy results from all 1433 randomised … Molnupiravir attacks the
coronavirus by triggering an … the drug’s impact on coronavirus genes. While its mutagenic effect is …

… for the treatment of mild to moderate COVID-19 in … safety profile and risk of DILI with
molnupiravir and ritonavir-boosted nirmatrelvir in COVID-19 patients amidst the peak of the COVID…

… Observational studies of nirmatrelvir/ritonavir or molnupiravir compared to no antiviral
drug treatment for COVID-19 in non-hospitalized adults with data on vaccination status were …

… -analysis evaluated the efficacy and safety of three new antivirals (remdesivir, nirmatrelvir/ritonavir,
and molnupiravir) for treating mild to moderate COVID-19 outpatients. We included …

… or molnupiravir could reduce the overall risk of hospitalisation or death in patients at high risk
with mild-to-moderate COVID-… safety of VV116 in patients with mild-to-moderate COVID-19. …

… The efficacy and safety of molnupiravir were investigated in the phase III part of the global
MOVe-OUT study in outpatients with mild-tomoderate COVID-19 who were at risk for severe …

… with coronavirus disease 2019 (COVID-19) with normal or mild renal … safety and efficacy of
nirmatrelvir-ritonavir when compared with molnupiravir in the treatment of patients with COVID…

… -2021, there were several COVID-19 treatments for patients with mild to moderate disease …
death in patients with COVID-19. We evaluated molnupiravir pharmacokinetics and safety in a …